[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Mastrangelo S, Tornesello A, Diociaiuti L, Pession A, Prete A, Rufini V, Troncone L, Mastrangelo R: Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy. Br J Cancer; 2001 Feb;84(4):460-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.
  • Biological and clinical observations suggest that initial marked reduction of resistant clones may be critical in any attempt to improve long-term results in advanced neuroblastoma (NB).
  • The aim of this pilot study is to determine short-term toxicity and efficacy of a new therapeutic model based on the simultaneous use of multiple drug chemotherapy and specific irradiation using 131-I-MIBG.
  • In Group 1 (9 patients) the basic chemotherapy regimen consisted in cisplatin at the dose of 20 mg/m(2) i.v. per day infused over 2 h, for 4 consecutive days; on day 4 Cy 2 g/m(2) i.v. was administered over 2 h followed by Mesna.
  • Assessment of tumour response was monitored 4-6 weeks after the beginning of combined therapy (CO-TH).
  • Response was defined according to INSS (International Neuroblastoma Staging System) criteria.
  • Haematological toxicity was the only toxicity observed and seemed mainly related to chemotherapy.
  • No alteration in 131-I-MIBG uptake was observed after the chemotherapy preceding radio-metabolic treatment.
  • The therapeutic results of this pilot regimen of CO-TH resulted in a high percentage of major response after only a single course in both resistant patients and patients treated at diagnosis.
  • Because of the minimal toxicity observed in patients studied at diagnosis so far, there is room for gradual intensification of the treatment.
  • [MeSH-major] 3-Iodobenzylguanidine / therapeutic use. Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / radiotherapy. Adrenal Gland Neoplasms / drug therapy. Adrenal Gland Neoplasms / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Iodine Radioisotopes / therapeutic use. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / radiotherapy. Neuroblastoma / drug therapy. Neuroblastoma / radiotherapy. Radiopharmaceuticals / therapeutic use
  • [MeSH-minor] Child. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Female. Humans. Infant. Infusions, Intravenous. Male. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Cancer Research Campaign.
  • [Cites] Med Pediatr Oncol. 1993;21(6):411-5 [8515721.001]
  • [Cites] J Clin Oncol. 1992 Dec;10(12):1889-96 [1453204.001]
  • [Cites] Eur J Cancer. 1995;31A(4):600-2 [7576977.001]
  • [Cites] Eur J Cancer. 1995;31A(4):606-11 [7576979.001]
  • [Cites] J Neurooncol. 1997 Jan;31(1-2):153-8 [9049843.001]
  • [Cites] Br J Cancer. 1997;75(4):470-6 [9052395.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):229-36 [9440747.001]
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1165-73 [10519894.001]
  • [Cites] Cancer Treat Rep. 1976 Apr;60(4):409-14 [1277215.001]
  • [Cites] Cell Tissue Kinet. 1978 Sep;11(5):543-53 [719696.001]
  • [Cites] J Nucl Med. 1980 Apr;21(4):349-53 [7381563.001]
  • [Cites] J Clin Oncol. 1984 Jul;2(7):717-8 [6737017.001]
  • [Cites] J Nucl Med. 1985 Jul;26(7):736-42 [4009283.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):941-50 [3585448.001]
  • [Cites] Med Pediatr Oncol. 1987;15(4):157-8 [3657703.001]
  • [Cites] Med Pediatr Oncol. 1987;15(4):188-91 [3657705.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1989 Spring;11(1):28-31 [2785352.001]
  • [Cites] Br J Cancer. 1990 Aug;62(2):319-23 [2386751.001]
  • [Cites] Radiother Oncol. 1991 Jul;21(3):149-56 [1924849.001]
  • [Cites] J Nucl Biol Med. 1991 Oct-Dec;35(4):260-2 [1823831.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1592-601 [1403039.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1466-77 [8336186.001]
  • (PMID = 11207038.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 35MRW7B4AD / 3-Iodobenzylguanidine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2363758
  •  go-up   go-down


2. Kapoor V, Lodha R, Agarwala S: Superior mediastinal syndrome with Rowland-Payne syndrome: an unusual presentation of cervico-mediastinal neuroblastoma. Pediatr Blood Cancer; 2005 Mar;44(3):280-2
MedlinePlus Health Information. consumer health - Paralysis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superior mediastinal syndrome with Rowland-Payne syndrome: an unusual presentation of cervico-mediastinal neuroblastoma.
  • A 5-month-old boy presented with superior mediastinal syndrome due to a large, unresectable cervico-mediastinal neuroblastoma.
  • He had an unusual constellation of findings not previously reported in neuroblastoma: Horner syndrome, phrenic nerve palsy, and palsy of the ipsilateral recurrent laryngeal nerve.
  • The child required prolonged mechanical ventilation but responded to chemotherapy and is now free of tumor and completely recovered.
  • [MeSH-major] Head and Neck Neoplasms / complications. Horner Syndrome / etiology. Mediastinal Diseases / etiology. Mediastinal Neoplasms / complications. Neuroblastoma / complications. Paralysis / etiology. Phrenic Nerve. Vocal Cord Paralysis / etiology

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15503296.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Shimizu M, Shimizu T, Adachi T, Nishiuchi M, Kanzaki M, Onuki T: Long-term survival in adult mediastinal neuroblastoma. Jpn J Thorac Cardiovasc Surg; 2003 Jul;51(7):326-9
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in adult mediastinal neuroblastoma.
  • Neuroblastoma rarely occurs in adults, in whom prognosis is poor.
  • Here we report on the effective use of multimodal therapy to achieve long-term survival in adult mediastinal neuroblastoma.
  • Chest X-rays and chest CT scans revealed a posterior mediastinal mass beside the thoracic vertebrae.
  • Diagnosis was confirmed after surgical resection, which was followed by outpatient adjuvant therapy through radiation and chemotherapy.
  • [MeSH-major] Mediastinal Neoplasms / mortality. Neuroblastoma / mortality
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Humans. Male. Radiotherapy, Adjuvant. Survival Analysis. Thoracotomy. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12892467.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyōbu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


Advertisement
4. Gambini JP, López Lerena JJ, Quagliata A, Hermida JC, Heuguerot C, Alonso O: 99mTc-HYNIC octreotide in neuroblastoma. Ann Nucl Med; 2008 Nov;22(9):817-9
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 99mTc-HYNIC octreotide in neuroblastoma.
  • Disease status assessment of neuroblastoma patients requires computed tomography (or magnetic resonance imaging), bone scan, metaiodobenzylguanidine (MIBG) scan, bone marrow tests, and urine catecholamine measurements.
  • An 8-year-old boy already diagnosed with stage-IV neuroblastoma received chemotherapy.
  • Even as the 131I-IBG scan showed mild diffuse uptake in the projection of both lung hili, the 99mTc-HYNIC-octreotide scan showed multiple axial and appendicular bone uptakes and paravertebral, abdominal, mediastinal, and supraclavicular ganglionar uptakes.
  • Therefore, 99mTc-HYNIC-octreotide may be a promising radiopharmaceutical for the evaluation of neuroblastoma patients.
  • [MeSH-major] 3-Iodobenzylguanidine. Adrenal Gland Neoplasms / radionuclide imaging. Neuroblastoma / radionuclide imaging. Octreotide / analogs & derivatives. Organotechnetium Compounds

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19039561.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m hydrazinonicotinyl-Tyr(3)-octreotide; 35MRW7B4AD / 3-Iodobenzylguanidine; RWM8CCW8GP / Octreotide
  •  go-up   go-down


5. Schalk E, Mohren M, Koenigsmann M, Buhtz P, Franke A, Jentsch-Ullrich K: Metastatic adrenal neuroblastoma in an adult. Onkologie; 2005 Jun;28(6-7):353-5
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adrenal neuroblastoma in an adult.
  • BACKGROUND: Neuroblastoma (NB) is a common malignancy in children, but rarely occurs in adults.
  • Chemotherapy according to the paediatric German Neuroblastoma Trial (NB97) was started.
  • Follow-up computed tomography showed regression of the enlarged mediastinal and retroperitoneal lymph nodes.
  • Currently there are no standard treatment guidelines for patients with NB in adulthood.
  • Collection and evaluation of data in adult patients with this tumour are warranted in order to optimise treatment strategies.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Neuroblastoma / pathology. Neuroblastoma / secondary

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933424.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


6. Kang CH, Kim YT, Jeon SH, Sung SW, Kim JH: Surgical treatment of malignant mediastinal neurogenic tumors in children. Eur J Cardiothorac Surg; 2007 Apr;31(4):725-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of malignant mediastinal neurogenic tumors in children.
  • INTRODUCTION: The aim of this study was to identify the role of surgical resection in the treatment of malignant mediastinal neurogenic tumors in children.
  • MATERIALS AND METHODS: Thirty-eight consecutive children, who underwent surgical resection of a malignant mediastinal neurogenic tumor between 1986 and 2004, were included in this study.
  • The tumor cell types were neuroblastoma in 23 patients (60.5%), ganglioneuroblastoma in 14 (36.8%), and malignant neuroepithelioma in 1 (2.6%).
  • Surgery was performed for curative resection in localized tumors and salvage resection of residual mediastinal masses after chemotherapy in stage IV tumors.
  • Of the 16 patients (42.1%) who underwent salvage resection, 14 had neuroblastoma and 2 ganglioneuroblastoma.
  • CONCLUSIONS: Surgical resection of localized malignant mediastinal neurogenic tumor in children showed good long-term survival, and salvage operations after chemotherapy showed acceptable long-term survival.
  • [MeSH-major] Mediastinal Neoplasms / surgery. Neuroectodermal Tumors, Primitive, Peripheral / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Ganglioneuroblastoma / mortality. Ganglioneuroblastoma / surgery. Humans. Infant. Infant, Newborn. Male. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Neuroblastoma / mortality. Neuroblastoma / surgery. Postoperative Complications. Preoperative Care / methods. Retrospective Studies. Risk Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306984.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


7. Gao XN, Tang SQ, Lin J: [Clinical features and prognosis of advanced neuroblastoma in children]. Zhongguo Dang Dai Er Ke Za Zhi; 2007 Aug;9(4):351-4
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and prognosis of advanced neuroblastoma in children].
  • OBJECTIVE: To investigate the clinical features, treatment modalities and the prognosis of advanced neuroblastoma in children.
  • METHODS: The medical records of 63 children with stage III or IV neuroblastoma from January 1996 to December 2005 were retrospectively reviewed.
  • Sixty patients were treated by tumor resection and (or) chemotherapy and (or) radiation.
  • RESULTS: Of the 63 patients with advanced neuroblastoma, the male/female ratio was 2.7:1 and the median age at diagnosis was 4 years old.
  • Primary tumor sites were adrenal (38%), retroperitoneal (35%), mediastinal (17%), pelvic (6%) and cervical (2%).
  • The median survival time of the 63 patients was 32.7 months.
  • Intensive chemotherapy in combination with autologous peripheral blood stem cell transplantation could also result in a prolonged overall survival period (P < 0.01).
  • CONCLUSIONS: Neuroblastoma with advanced stages often presents with various clinical manifestations and has a poor prognosis.
  • It is beneficial to improve the prognosis of neuroblastoma through an early diagnosis and a comprehensive therapy including total resection of the primary tumor, autologous peripheral blood stem cell transplantation and intensive chemotherapy.
  • [MeSH-major] Neuroblastoma / mortality
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Prognosis

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706038.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Yiin JJ, Chang CS, Jan YJ, Wang YC: Treatment of neuroblastoma with intraspinal extensions. J Clin Neurosci; 2003 Sep;10(5):579-83
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of neuroblastoma with intraspinal extensions.
  • Neuroblastoma is the most common malignant cause of spinal compression in the paediatric population.
  • Chemotherapy is commonly considered as the first-line treatment for these patients.
  • Thirteen children diagnosed as having neuroblastoma with intraspinal extension were included in this report.
  • All patients presented with neurological deficits and were treated with chemotherapy initially, after which 3 patients recovered, 4 improved and 6 were aggravated into paraplegia.
  • Although spread of tumour into the spinal canal indicates an advanced disease, aggressive treatments such as chemotherapy and surgical resection can often improve neurological symptoms and life quality.
  • Neurological decompression is recommended for patients with intraspinal neuroblastoma and rapid neurological deterioration during chemotherapy.
  • [MeSH-major] Neuroblastoma / surgery. Spinal Neoplasms / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Mediastinal Neoplasms / pathology. Neoplasm Invasiveness. Retroperitoneal Neoplasms / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12948463.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


9. Sucker C, Dölken G, Lorenz G, Fiedler W, Stockschläder M: [Thoracic neuroblastoma in a young adult]. Dtsch Med Wochenschr; 2004 Feb 6;129(6):249-52
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thoracic neuroblastoma in a young adult].
  • EXAMINATIONS: Diagnostic imaging showed an extensive thoracic tumor and enlarged mediastinal and cervical lymph nodes.
  • The diagnosis of neuroblastoma was established by biopsy.
  • TREATMENT AND CLINICAL COURSE: The patient was treated with a polychemotherapy protocol according to the pediatric neuroblastoma study NB97.
  • Subsequently, the patient underwent partial tumor resection, received two further chemotherapy courses and irradiation of the remaining tumor.
  • Because of residual vital tumor cells, a second surgical tumour reduction followed by high-dose chemotherapy with autologous stem-cell support was performed.
  • Six months after the end of therapy, the patient is in a good condition despite of the presence of residual tumor.
  • CONCLUSION: Neuroblastoma is a very rare tumor in adult patients.
  • Therapy is multimodal and should follow pediatric guidelines for neuroblastoma treatment.
  • [MeSH-major] Neuroblastoma / diagnosis. Neuroblastoma / therapy. Thoracic Neoplasms / diagnosis. Thoracic Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Radiotherapy, Adjuvant. Reoperation. Stem Cell Transplantation. Transplantation, Autologous. Tretinoin / administration & dosage

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14750051.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 5688UTC01R / Tretinoin
  •  go-up   go-down


10. Moon SB, Park KW, Jung SE, Youn WJ: Neuroblastoma: treatment outcome after incomplete resection of primary tumors. Pediatr Surg Int; 2009 Sep;25(9):789-93
Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroblastoma: treatment outcome after incomplete resection of primary tumors.
  • PURPOSE: For International Neuroblastoma Staging System (INSS) stages III or IV neuroblastoma (intermediate or high risk), complete excision of the primary tumor is not always feasible.
  • Most current studies on the treatment outcome of these patients have reported on the complete excision status.
  • The aim of this study is to review the treatment outcome after the incomplete resection.
  • Incomplete resection was assessed by review of the operative notes and postoperative computerized tomography.
  • Age, gender, tumor location, INSS stage, N-myc gene copy number, pre- and postoperative therapy, and treatment outcome were reviewed.
  • The treatment outcome was evaluated according to the postoperative treatment protocol in the high-risk group.
  • RESULTS: Intermediate-risk patients were treated with conventional chemotherapy, isotretinoin (ITT) and interleukin-2 (IL-2).
  • Before the introduction of PBSCT, the high-risk patients were also treated with the conventional chemotherapy (N = 19).
  • For the high-risk patients (N = 32), 19 patients were treated with chemotherapy alone; 15 patients died of their disease while four patients currently have an NED status.
  • CONCLUSIONS: For intermediate risk, conventional chemotherapy appears to be acceptable treatment.
  • However, for high-risk patients, every effort should be made to control residual disease including the use of myeloablative chemotherapy, differentiating agents and immune-modulating agents.
  • [MeSH-major] Neuroblastoma / mortality. Neuroblastoma / therapy
  • [MeSH-minor] Adrenal Gland Neoplasms / mortality. Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / therapy. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Dermatologic Agents / therapeutic use. Female. Follow-Up Studies. Genes, myc. Humans. Infant. Interleukin-2 / therapeutic use. Isotretinoin / therapeutic use. Male. Mediastinal Neoplasms / mortality. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / therapy. Neoplasm, Residual. Pelvic Neoplasms / mortality. Pelvic Neoplasms / pathology. Pelvic Neoplasms / therapy. Peripheral Blood Stem Cell Transplantation. Radiotherapy, Adjuvant. Retroperitoneal Neoplasms / mortality. Retroperitoneal Neoplasms / pathology. Retroperitoneal Neoplasms / therapy. Retrospective Studies

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1256-64 [9552023.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1007-13 [19171716.001]
  • [Cites] Semin Surg Oncol. 1993 Nov-Dec;9(6):489-92 [8284567.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2891-6 [16782928.001]
  • [Cites] J Neuroimmunol. 1999 May 3;96(2):201-6 [10337918.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1706-15 [9473237.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):953-65 [9508178.001]
  • [Cites] J Pediatr Surg. 2002 Nov;37(11):1574-8 [12407542.001]
  • [Cites] Cancer Lett. 2003 Jul 18;197(1-2):185-92 [12880980.001]
  • [Cites] J Pediatr Surg. 2004 Mar;39(3):412-7; discussion 412-7 [15017562.001]
  • [Cites] Eur J Cancer. 1997 Oct;33(12):2024-30 [9516847.001]
  • [Cites] J Korean Med Sci. 2003 Apr;18(2):242-7 [12692423.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2417-26 [8823319.001]
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1165-73 [10519894.001]
  • [Cites] J Hematother. 1997 Jun;6(3):235-42 [9234178.001]
  • [Cites] J Pediatr Surg. 2004 Jun;39(6):931-6 [15185228.001]
  • [Cites] Bone Marrow Transplant. 1999 Jan;23 (2):169-72 [10197803.001]
  • (PMID = 19629500.001).
  • [ISSN] 1437-9813
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Dermatologic Agents; 0 / Interleukin-2; EH28UP18IF / Isotretinoin
  •  go-up   go-down


11. DeCou JM, Schlatter MG, Mitchell DS, Abrams RS: Primary thoracoscopic gross total resection of neuroblastoma. J Laparoendosc Adv Surg Tech A; 2005 Oct;15(5):470-3
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary thoracoscopic gross total resection of neuroblastoma.
  • PATIENTS AND METHODS: We reviewed the records of patients who underwent primary thoracoscopic resection of neuroblastoma (NB) between 1998 and 2002.
  • Data included demographics, symptoms, size, location, operative time, complications, hospital stay, histology, biologic markers, adjuvant therapy, and outcome.
  • Operative time ranged from 64 to 175 minutes.
  • Chemotherapy or radiation therapy was not indicated for any patient.
  • CONCLUSION: Primary gross total resection of mediastinal NB can be achieved safely and effectively by a thoracoscopic approach.
  • [MeSH-major] Neuroblastoma / surgery. Thoracic Neoplasms / surgery. Thoracoscopy

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185118.001).
  • [ISSN] 1092-6429
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Boutros J, Bond M, Beaudry P, Blair GK, Skarsgard ED: Case selection in minimally invasive surgical treatment of neuroblastoma. Pediatr Surg Int; 2008 Oct;24(10):1177-80
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case selection in minimally invasive surgical treatment of neuroblastoma.
  • PURPOSE: The experience with minimally invasive surgery (MIS) in the treatment of neuroblastoma (NB) is anecdotal.
  • Six of the eight (75%) tumors were adrenal in origin and the remainder were located in the posterior mediastinum.
  • Distribution by International Neuroblastoma Staging System (INSS) stage was: stage 1 (3), stage 2 (2), and stage 4 (3).
  • All stage 4 patients experienced a >50% tumor volume cytoreduction in response to preoperative chemotherapy.
  • All MIS resections were performed without need for blood transfusion, or conversion to open procedure, and there were no perioperative complications.
  • [MeSH-major] Minimally Invasive Surgical Procedures. Neuroblastoma / surgery. Patient Selection
  • [MeSH-minor] Adolescent. Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / surgery. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Male. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / surgery. Neoadjuvant Therapy. Retroperitoneal Neoplasms / pathology. Retroperitoneal Neoplasms / surgery. Retrospective Studies

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1995 Jul 1;76(1):121-8 [8630863.001]
  • [Cites] Arch Surg. 2005 Sep;140(9):905-8; discussion 909 [16175699.001]
  • [Cites] JSLS. 2004 Apr-Jun;8(2):115-8 [15119653.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2005 Feb;15(1):80-3 [15772485.001]
  • [Cites] J Pediatr Surg. 2002 Jul;37(7):979-82; discussion 979-82 [12077753.001]
  • [Cites] Surg Endosc. 2001 Feb;15(2):156-60 [11285959.001]
  • [Cites] J Urol. 2003 Sep;170(3):932-5 [12913744.001]
  • [Cites] Surg Endosc. 2001 Jul;15(7):751-4 [11591983.001]
  • [Cites] Pediatr Surg Int. 2004 Jan;20(1):39-42 [14691638.001]
  • [Cites] Med Pediatr Oncol. 2003 Mar;40(3):155-7 [12518343.001]
  • [Cites] Semin Surg Oncol. 1999 Mar;16(2):184-92 [9988872.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2005 Oct;15(5):470-3 [16185118.001]
  • [Cites] Ann Surg Oncol. 2004 Mar;11(3):340-3 [14993031.001]
  • [Cites] J Am Coll Surg. 2006 Nov;203(5):699-703 [17084332.001]
  • [Cites] J Urol. 2002 Jul;168(1):221-4 [12050547.001]
  • [Cites] J Pediatr Surg. 2002 Mar;37(3):431-6 [11877662.001]
  • [Cites] Surg Endosc. 2003 Nov;17(11):1769-72 [12802670.001]
  • [Cites] Eur J Cancer. 1997 Oct;33(12):2130-5 [9516868.001]
  • [Cites] J Pediatr Surg. 2004 Jun;39(6):931-6 [15185228.001]
  • [Cites] J Pediatr Surg. 2005 Dec;40(12):1948-50 [16338326.001]
  • [Cites] J Pediatr Surg. 2004 May;39(5):764-7 [15137015.001]
  • [Cites] J Pediatr Surg. 2002 Jul;37(7):949-54 [12077747.001]
  • (PMID = 18716783.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Blokker RS, Smit LM, van den Bos C, Overberg PC, Caron HN, Kaspers GJ: [A boy with acute cerebellar ataxia without opsoclonus caused by neuroblastoma]. Ned Tijdschr Geneeskd; 2006 Apr 8;150(14):799-803
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A boy with acute cerebellar ataxia without opsoclonus caused by neuroblastoma].
  • After a period of years a neuroblastoma was detected.
  • Treatment with a curative intent was successful and consisted of metaiodobenzylguanidine I 131, chemotherapy, tumour resection, chemotherapy again and follow-up treatment with isotretinoin after irradiation.
  • In the literature, 5 other children have been described with acute cerebellar ataxia without opsoclonus in whom neuroblastoma was detected eventually.
  • The mean time between initial presentation and diagnosis ofneuroblastoma or ganglioneuroblastoma was 12 months.
  • Ataxia resolved following resection of the neuroblastoma in all patients.
  • Each child with prolonged or recurrent acute cerebellar ataxia should be extensively investigated for the presence of neuroblastoma, even in the absence of opsoclonus.
  • [MeSH-major] Cerebellar Ataxia / etiology. Mediastinal Neoplasms / complications. Neuroblastoma / complications

  • Genetic Alliance. consumer health - Cerebellar Ataxia.
  • Genetic Alliance. consumer health - Neuroblastoma.
  • Genetic Alliance. consumer health - Ataxia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16649400.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


14. Gutierrez JC, Cheung MC, Zhuge Y, Koniaris LG, Sola JE: Does Children's Oncology Group hospital membership improve survival for patients with neuroblastoma or Wilms tumor? Pediatr Blood Cancer; 2010 Oct;55(4):621-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does Children's Oncology Group hospital membership improve survival for patients with neuroblastoma or Wilms tumor?
  • PURPOSE: To determine prognostic significance of hospital surgical volume and Children's Oncology Group (COG) membership on neuroblastoma (NBL) and Wilms tumor (WT) survival.
  • COG hospitals treated a larger proportion of patients <1 year of age (P = 0.002) and relatively more patients with adrenal and mediastinal tumors (P = 0.005).
  • COG centers more frequently administered chemotherapy (72% vs. 51%, P < 0.001).
  • COG centers more frequently administered chemotherapy (88% vs. 59%, P < 0.001).
  • CONCLUSION: Children treated at COG hospitals had higher overall use of chemotherapy.
  • [MeSH-major] Kidney Neoplasms / mortality. Neuroblastoma / mortality. Outcome and Process Assessment (Health Care). Wilms Tumor / mortality


15. Onitake Y, Hiyama E, Kamei N, Yamaoka H, Sueda T, Hiyama K: Telomere biology in neuroblastoma: telomere binding proteins and alternative strengthening of telomeres. J Pediatr Surg; 2009 Dec;44(12):2258-66
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomere biology in neuroblastoma: telomere binding proteins and alternative strengthening of telomeres.
  • PURPOSE: Neuroblastoma (NBL) shows remarkable biologic heterogeneity, resulting in favorable or unfavorable prognoses.
  • High-dose chemotherapy did not have much effect on these deceased ALT cases, but their survival periods were more than 2 years and relatively long compared with the deceased cases with nonelongated telomeres, suggesting that chemoresistance in ALT tumors may be related to slow growth rates.
  • [MeSH-major] Neuroblastoma / genetics. Telomere / ultrastructure. Telomere-Binding Proteins / metabolism
  • [MeSH-minor] Adolescent. Adrenal Gland Neoplasms / genetics. Adrenal Gland Neoplasms / metabolism. Adrenal Gland Neoplasms / mortality. Blotting, Southern / statistics & numerical data. Child. Child, Preschool. Disease-Free Survival. Drug Resistance, Neoplasm / genetics. Flow Cytometry / statistics & numerical data. Humans. Mass Screening / statistics & numerical data. Mediastinal Neoplasms / genetics. Mediastinal Neoplasms / metabolism. Mediastinal Neoplasms / mortality. Ploidies. Prognosis. Retroperitoneal Neoplasms / genetics. Retroperitoneal Neoplasms / metabolism. Retroperitoneal Neoplasms / mortality. Survival Analysis. Tandem Repeat Sequences / genetics. Telomerase / genetics. Telomerase / metabolism

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20006006.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Telomere-Binding Proteins; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


16. Escobar MA, Grosfeld JL, Powell RL, West KW, Scherer LR 3rd, Fallon RJ, Rescorla FJ: Long-term outcomes in patients with stage IV neuroblastoma. J Pediatr Surg; 2006 Feb;41(2):377-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes in patients with stage IV neuroblastoma.
  • AIM OF STUDY: Long-term outcome studies in survivors with stage IV neuroblastoma (NB) are sparse.
  • Primary tumor sites were adrenal (35), retroperitoneal (11), mediastinal (3), pelvic (2), and no primary with tumor metastases identified (1).
  • Treatment in survivors included surgery in 51 (75% [39/51] complete tumor resection [CTR]); chemotherapy, 50; radiation, 17; stem cell transplantation, 20; and bone marrow transplant, 1.
  • Recurrence was local (1), distant (2), and both (3) and was treated by resection, chemotherapy, and radiation.
  • CONCLUSION: Only 34% of patients with stage IV NB survived despite aggressive multimodal therapy.
  • New methods of treatment are required to achieve better outcomes.
  • [MeSH-major] Neuroblastoma / pathology. Neuroblastoma / therapy. Survivors
  • [MeSH-minor] Child, Preschool. Female. Humans. Male. Neoplasm Staging. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16481255.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Ohtsuka M, Satoh H, Inoue M, Yazawa T, Yamashita YT, Sekizawa K, Hasegawa S: Disseminated metastasis of neuroblastomatous component in immature mediastinal teratoma: a case report. Anticancer Res; 2000 Jan-Feb;20(1B):527-30
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated metastasis of neuroblastomatous component in immature mediastinal teratoma: a case report.
  • A 17-year-old man with high levels of serum AFP and hCG was diagnosed as having primary mediastinal GCT.
  • Cisplatin-based chemotherapy decreased the biomarkers, but the mass showed further growth.
  • A disseminated metastasis of neuroblastoma in immature mediastinal teratoma is a rare complication.
  • [MeSH-major] Brain Neoplasms / secondary. Lung Neoplasms / secondary. Mediastinal Neoplasms / pathology. Neuroblastoma / secondary. Teratoma / pathology. Thymus Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Bleomycin / administration & dosage. Cell Lineage. Cisplatin / administration & dosage. Combined Modality Therapy. Disease Progression. Fatal Outcome. Humans. Male. Phosphopyruvate Hydratase / analysis. Skull Neoplasms / pathology. Skull Neoplasms / secondary. Vinblastine / administration & dosage


18. Castel V, Tovar JA, Costa E, Cuadros J, Ruiz A, Rollan V, Ruiz-Jimenez JI, Perez-Hernández R, Cañete A: The role of surgery in stage IV neuroblastoma. J Pediatr Surg; 2002 Nov;37(11):1574-8
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of surgery in stage IV neuroblastoma.
  • BACKGROUND/PURPOSE: The importance of primary tumor resection in stage IV neuroblastoma is controversial.
  • The authors analyzed prospectively the role of surgery in a multicentric series of stage IV neuroblastoma patients.
  • METHODS: Patients were studied according to the International Neuroblastoma Staging System (INSS) recommendations.
  • Age, sex, location of the tumor, type of metastases, time of resection (initial or delayed), extension of resection, surgical complications, pathology, N-myc and Shimada classification results, relapses, and outcome were studied.
  • After diagnosis, children received induction chemotherapy followed by delayed surgery and autologous stem cell transplantation or maintenance chemotherapy.
  • Mean survival rate time was 50 months.
  • EFS rate for infants was 0.56, but, again, there was no difference in relation to the type of resection.
  • CONCLUSIONS: Biopsies of stage IV neuroblastoma allow safe assessment of N-myc and other biological factors on tumor tissue.
  • Delayed surgery after chemotherapy is performed with a low rate of complications, achieving a good local control of disease.
  • N-myc-amplified tumors have higher local relapse rates than nonamplified and therefore would need more intensive local treatment.
  • [MeSH-major] Neuroblastoma / pathology. Neuroblastoma / surgery
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / mortality. Abdominal Neoplasms / pathology. Abdominal Neoplasms / surgery. Biopsy, Needle. Bone Marrow Neoplasms / secondary. Bone Neoplasms / secondary. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Lymphatic Metastasis. Male. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / mortality. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / surgery. Neoplasm Recurrence, Local. Neoplasm Staging. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12407542.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Miura K, Mineta H, Yokota N, Tsutsui Y: Olfactory neuroblastoma with epithelial and endocrine differentiation transformed into ganglioneuroma after chemoradiotherapy. Pathol Int; 2001 Dec;51(12):942-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfactory neuroblastoma with epithelial and endocrine differentiation transformed into ganglioneuroma after chemoradiotherapy.
  • We report a 56-year-old man in whom an olfactory neuroblastoma with epithelial and endocrine differentiation transformed into a mature ganglioneuroma after chemoradiotherapy.
  • A radical craniofacial resection of the primary tumor was performed after 16 Gy of local irradiation and systemic chemotherapy.
  • Three months after the operation, the patient died of mediastinal metastasis.
  • The biopsy before chemoradiotherapy showed a neuroblastoma with Homer-Wright rosettes, fibrillary matrix, Flexner-Wintersteiner rosettes and antidiuretic hormone production.
  • After chemoradiotherapy, the histology changed to that of a ganglioneuroma consisting of large ganglion cells and Schwann cells without immature neuroblastoma components.
  • Although transformation to ganglioneuroma in an adrenal neuroblastoma is common, an olfactory neuroblastoma showing ganglioneuronal maturation after chemoradiotherapy has not been reported.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carboplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Fatal Outcome. Humans. Inappropriate ADH Syndrome. Male. Middle Aged. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11844067.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


20. La Quaglia MP, Kushner BH, Su W, Heller G, Kramer K, Abramson S, Rosen N, Wolden S, Cheung NK: The impact of gross total resection on local control and survival in high-risk neuroblastoma. J Pediatr Surg; 2004 Mar;39(3):412-7; discussion 412-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of gross total resection on local control and survival in high-risk neuroblastoma.
  • BACKGROUND/PURPOSE: Gross total resection of the primary tumor in treatment of high-risk neuroblastoma remains controversial.
  • RESULTS: The median age was 3.3 years, and all patients were International Neuroblastoma Staging System (INSS) stage 4 with 79% having metastases to cortical bone.
  • The primary site was the adrenal gland in 74%, the central abdominal compartment in 13%, the posterior mediastinum in 7%, and other sites in 6%.
  • CONCLUSIONS: Our data indicate that local control and overall survival rate are correlated with gross total resection of the primary tumor in high-risk neuroblastoma.
  • Gross total resection should be part of the management of stage 4 neuroblastoma in patients greater than 1 year of age.
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / surgery. Adrenal Gland Neoplasms / drug therapy. Adrenal Gland Neoplasms / surgery. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / surgery. Neuroblastoma / drug therapy. Neuroblastoma / surgery
  • [MeSH-minor] Adolescent. Adult. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Disease Progression. Humans. Infant. Iodine Radioisotopes. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15017562.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


21. Fukuda M, Miyajima Y, Miyashita Y, Horibe K: Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study. J Pediatr Hematol Oncol; 2001 Jan;23(1):10-3
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study.
  • PURPOSE: This pilot study focussed on whether sequential molecular detection of minimal residual disease (MRD) in bone marrow (BM) could predict the outcome of patients with advanced neuroblastoma.
  • PATIENTS AND METHODS: Bone marrow samples from 21 patients older than age 12 months with stage IV neuroblastoma were sequentially examined for tumor cell contamination by detecting tyrosine hydroxylase (TH) messenger ribonucleic acid (mRNA) using reverse transcription-polymerase chain reaction (RT-PCR).
  • Twenty patients received myeloablative therapy with hematopoietic stem cell transplantation after achieving complete remission.
  • RESULTS: All BM samples of patients except that of one patient was cytologically positive for neuroblastoma cells at diagnosis, and they became negative for neuroblastoma cells within 3 months by cytologic examination.
  • By RT-PCR analysis, BM samples of all patients were positive for TH mRNA at diagnosis, and samples of 19 patients became negative for TH mRNA 1 to 13 months after the start of chemotherapy.
  • Six patients whose BM samples became negative for TH mRNA within 4 months after the start of chemotherapy remained alive without evidence of disease (median 76 mos, range 36-91).
  • CONCLUSION: Persistence of MRD in BM may predict poor prognosis in advanced neuroblastoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Bone Neoplasms / secondary. Hematopoietic Stem Cell Transplantation. Neoplasm, Residual / pathology. Neuroblastoma / pathology. Neuroblastoma / secondary
  • [MeSH-minor] Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / therapy. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / therapy. Neoplasm Metastasis. Pilot Projects. RNA, Messenger / analysis. Retroperitoneal Neoplasms / pathology. Retroperitoneal Neoplasms / therapy. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Treatment Outcome. Tyrosine 3-Monooxygenase / genetics

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11196262.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Messenger; EC 1.14.16.2 / Tyrosine 3-Monooxygenase
  •  go-up   go-down


22. Nishio N, Mimaya J, Nara T, Takashima Y, Horikoshi Y, Urushihara N, Hasegawa S, Aoki K, Hamasaki M: Results for 79 patients with neuroblastoma detected through mass screening at 6 months of age in a single institute. Pediatr Int; 2006 Dec;48(6):531-5
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results for 79 patients with neuroblastoma detected through mass screening at 6 months of age in a single institute.
  • BACKGROUND: In Japan, mass screening for neuroblastoma has been performed at 6 months of age to improve the prognosis of this condition for more than 20 years.
  • METHODS: The authors established non-treated observation criteria in 1997 and criteria for observation of residual tumor after first-line chemotherapy in 1999, and have made an effort to reduce the intensity of medical treatment for neuroblastoma.
  • The authors examined outcomes of 79 patients who were found in the Shizuoka neuroblastoma mass screening at 6 months of age and who received medical treatment or underwent observation in Shizuoka Children's Hospital, Shizuoka, Japan, between December 1981 and December 2004.
  • RESULTS: A total of 77 patients survived but the remaining two patients died from complications of medical treatment.
  • None of the patients died due to progression of neuroblastoma.
  • Observation of residual tumor after first-line chemotherapy was performed in 15 cases, and three disappeared and the other 12 cases became smaller.
  • Medical treatment-related complications were observed in 20 of 67 patients who received medical treatment, and 18 of the 20 patients were seen before establishing non-treated observation criteria.
  • CONCLUSION: Non-treated observation and observation of residual tumor after first-line chemotherapy were useful to reduce medical treatment-related complications.
  • [MeSH-major] Mass Screening. Neuroblastoma / diagnosis. Neuroblastoma / therapy
  • [MeSH-minor] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / urine. Homovanillic Acid / urine. Humans. Infant. Japan / epidemiology. Mediastinal Neoplasms / diagnosis. Mediastinal Neoplasms / therapy. Neoplasm Regression, Spontaneous. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome. Vanilmandelic Acid / urine

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168969.001).
  • [ISSN] 1328-8067
  • [Journal-full-title] Pediatrics international : official journal of the Japan Pediatric Society
  • [ISO-abbreviation] Pediatr Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 55-10-7 / Vanilmandelic Acid; X77S6GMS36 / Homovanillic Acid
  •  go-up   go-down


23. Dickson PV, Hamner JB, Burger RA, Garcia E, Ouma AA, Kim SU, Ng CY, Gray JT, Aboody KS, Danks MK, Davidoff AM: Intravascular administration of tumor tropic neural progenitor cells permits targeted delivery of interferon-beta and restricts tumor growth in a murine model of disseminated neuroblastoma. J Pediatr Surg; 2007 Jan;42(1):48-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular administration of tumor tropic neural progenitor cells permits targeted delivery of interferon-beta and restricts tumor growth in a murine model of disseminated neuroblastoma.
  • METHODS: Disseminated neuroblastoma was established in SCID mice by tail vein injection of tumor cells.
  • Control mice received NPCs transduced with empty vector adenovirus at the same time points.
  • RESULTS: After initiation of therapy, BLI demonstrated a significant decrease in the rate of disease progression in mice receiving F3-IFN-beta.
  • At necropsy, control mice had bulky tumor replacing the liver and kidneys, as well as extensive retroperitoneal and mediastinal adenopathy.
  • Impressively, these sites within mice receiving F3-IFN-beta therapy appeared grossly normal with the exception of small nodules within the kidneys of some of the F3-IFN-beta-treated mice.
  • CONCLUSIONS: These data indicate that in this model of disseminated neuroblastoma, the tumor-tropic property of F3.C1 NPCs was exploited to target delivery of IFN-beta to disseminated tissue foci, resulting in significant tumor growth delay.
  • The described novel approach for effective IFN-beta therapy may circumvent limitations associated with the systemic toxicity of IFN-beta.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Genetic Therapy / methods. Interferon-beta / administration & dosage. Stem Cells / physiology
  • [MeSH-minor] Adenoviridae. Animals. Cell Line. Cell Line, Tumor. Cell Movement. Disease Models, Animal. Disease Progression. Drug Delivery Systems / methods. Genetic Vectors. Humans. Injections, Intravenous. Mice. Mice, SCID. Neuroblastoma. Transduction, Genetic. Tumor Burden


24. Yang WP, Zou Y, Huang CS, Zhang SZ, Xiao Q, Dai KL, Zhong HS, Xiong XJ: [Clinicopathologic and prognostic study of pediatric immature teratoma]. Zhonghua Bing Li Xue Za Zhi; 2007 Oct;36(10):666-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Amongst the 39 cases studied, 12 arose in the sacrococcygeal region, 12 in testis, 5 in retroperitoneum, 4 in ovary, 4 in abdomen and 2 in mediastinum.
  • Immature neuroepithelial features used in histologic grading included the presence of primitive neural tubules, immature rosettes, undifferentiated neuroblastoma cells and primitive neuroectodermal structures.
  • Sacrococcygeal immature teratoma occurring in patients younger than 1 year old and with low histologic grade do not require postoperative chemotherapy if the tumor is completely excised.
  • Similarly, for testicular immature teratoma occurring in patients below 1 year of age, regardless of tumor grading, need no adjunctive therapy.
  • On the other hand, ovarian immature teratoma with high histologic grade requires postoperative chemotherapy, regardless of age of the patients.
  • [MeSH-minor] Adolescent. Cyclin D1 / metabolism. Endodermal Sinus Tumor / drug therapy. Endodermal Sinus Tumor / metabolism. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / surgery. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Ki-67 Antigen / metabolism. Male. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / metabolism. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / surgery. Neoplasm Recurrence, Local. Neoplasm Staging. Proliferating Cell Nuclear Antigen / metabolism. Sacrococcygeal Region. Survival Rate. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18194599.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / alpha-Fetoproteins; 0 / p27 antigen; 136601-57-5 / Cyclin D1
  •  go-up   go-down


25. Tang KT, Lee HC, Liang DC, Chen SH, Liu HC, Sheu JC: Neural-crest tumor presenting with chronic diarrhea: a report of three cases. J Formos Med Assoc; 2002 Dec;101(12):864-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A posterior mediastinal mass or abdominal mass found on sonography and chest roentgenography eventually led to the diagnosis of neural-crest tumor in these patients.
  • Pathology revealed ganglioneuroblastoma in two cases and neuroblastoma in one.
  • All three patients received chemotherapy and underwent surgery.
  • Although one of the patients died of septic shock during chemotherapy, the other two remained free of disease at 30 and 22 months of postoperative follow-up, respectively.


26. Lejus C: [Anaesthetic particularities for children with tumours]. Ann Fr Anesth Reanim; 2006 Apr;25(4):424-31
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In children less than 5 years of age, neuroblastoma and nephroblastoma are the more frequent of the tumour.
  • However a general anaesthesia is required in numerous situations: bone marrow aspiration and biopsy, central venous catheter insertion, various biopsies under computed tomography, ultrasound, thoracoscopy or laparoscopy, MRI scan, surgery and body radiation.
  • Particularly, cardiotoxicity may result from chemotherapy and hypertension is frequently associated with neuroblastoma and nephroblastoma.
  • Mediastinal location of lymphomas induced a significant risk of cardiopulmonary complications during induction of general anaesthesia.
  • [MeSH-minor] Age Factors. Anthracyclines / adverse effects. Antibiotic Prophylaxis. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Blood Transfusion. Cardiomyopathies / chemically induced. Child. Child, Preschool. Humans. Infant. Infant, Newborn. Preoperative Care. Radiotherapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16310335.001).
  • [ISSN] 0750-7658
  • [Journal-full-title] Annales françaises d'anesthèsie et de rèanimation
  • [ISO-abbreviation] Ann Fr Anesth Reanim
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antineoplastic Agents
  • [Number-of-references] 42
  •  go-up   go-down


27. Oguz A, Karadeniz C, Citak EC, Conly NA, Ileri F, Boyunaga O, Okur V, Uluoglu O: Thymic and adenotonsillar enlargement after successful treatment of malignancies. Pediatr Hematol Oncol; 2005 Jul-Aug;22(5):423-35
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymic and adenotonsillar enlargement after successful treatment of malignancies.
  • Anterior mediastinal and adenoid masses in children after cessation of chemotherapy for malignant disease often cause a diagnostic problem.
  • Thymic hyperplasia was seen in 18 patients (5 Hodgkin disease (HD), 5 non-Hodgkin lymphoma (NHL), 4 Wilms tumor, 2 germ cell tumor, 1 Ewing sarcoma, and 1 neuroblastoma), only adenotonsillar hyperplasia was seen in 6 patients, all with NHL, and both thymic and adenotonsillar hyperplasia were seen in 3 patients (1 HD, 2 NHL).
  • The authors recommend that patients with thymic and/or adenotonsillar enlargement after successful treatment of their primary malignancy should be evaluated cautiously before an invasive procedure is planned.
  • [MeSH-major] Adenoids / pathology. Neoplasms / therapy. Thymus Gland / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Adenoids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16020133.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Castellani MR, Chiti A, Seregni E, Bombardieri E: Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan. Q J Nucl Med; 2000 Mar;44(1):77-87

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.
  • BACKGROUND: 45 patients with neuroendocrine tumours (22 neuroblastomas, 10 phaeochromocytomas, 3 para-gangliomas, 6 medullary thyroid carcinomas and 4 carcinoids) underwent 131I-MIBG therapy.
  • METHODS: All patients, with the exception of 5 phaeochromocytoma cases with nonoperable disease, had previously been treated with conventional therapies.
  • The therapeutic activity for adults ranged from 3.7 to 7.4 GBq of 131I-MIBG; for children from 2.7 to 5.5 GBq.
  • All treatments were repeated at not less than 4-weekly intervals.
  • The neuroblastoma patients were divided into two groups: the first included 14 patients with advanced metastatic disease not responding to previous treatments; the second included 8 patients with documented residual neuroblastoma tissue that could not be surgically removed after first-line therapy.
  • RESULTS: In neuroblastoma patients with advanced disease resistant to previous therapies 2 out of 14 showed a partial response, 9 stable disease and 3 progression of cancer.
  • In neuroblastoma patients with residual disease (7 evaluable out of 8) we obtained 3 partial responses; a stable response was observed in 3 patients.
  • The results of MIBG therapy in the group of phaeochromocytoma patients (9 evaluable out of 10) consisted of 3 partial responses, 5 stable disease and 1 progression.
  • Evaluation of the response carried out on the basis of biochemical parameters increased the responses and MIBG therapy showed good effectiveness in controlling the functional symptoms.
  • In patients with medullary thyroid carcinoma a partial response was observed in 1 patient with mediastinal metastases and 2 disease stabilisations were seen in another 2 patients.
  • Patients with carcinoids who underwent MIBG therapy showed 3 disease stabilisations.
  • The overall toxicity was acceptable, especially considering that the majority of our patients had had previous myelotoxic treatments (chemotherapy and/or radiotherapy, alone or in combination).
  • CONCLUSIONS: On the basis of our experience we can conclude that 131I-MIBG therapy is effective and also well tolerated.
  • [MeSH-major] 3-Iodobenzylguanidine / therapeutic use. Neuroendocrine Tumors / radiotherapy. Radiopharmaceuticals / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10932604.001).
  • [ISSN] 1125-0135
  • [Journal-full-title] The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)
  • [ISO-abbreviation] Q J Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ITALY
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 35MRW7B4AD / 3-Iodobenzylguanidine
  •  go-up   go-down


29. Shitara T, Shimada A, Tsuchida Y, Suzuki N, Toki F, Kuroiwa M: Successful clinical response to irinotecan in relapsed neuroblastoma. Med Pediatr Oncol; 2003 Feb;40(2):126-8
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful clinical response to irinotecan in relapsed neuroblastoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Lung Neoplasms / drug therapy. Mediastinal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Neuroblastoma / drug therapy
  • [MeSH-minor] Female. Humans. Infant. Salvage Therapy. Topoisomerase I Inhibitors. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12461801.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Topoisomerase I Inhibitors; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down






Advertisement